At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
RLYB Rallybio Corp.
Trading 08-11 10:12:57 EDT
16.81
+0.20
+1.20%
High16.81Low16.81Vol1.27K
Open16.81D1 Closing16.61Amplitude0.00%
Mkt Cap89.06MTradable Cap73.53MTotal Shares5.30M
T/O20.96KT/O Rate0.03%Tradable Shares4.37M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Rallybio Swings to Q2 Net Income of $43.67 Million; Operating Loss Narrows to $5.65 Million
Reuters  ·  08-06
Rallybio Swings to Q2 Net Income of $43.67 Million; Operating Loss Narrows to $5.65 Million
Rallybio to Merge with Avenzo, Shifting to Oncology
TIPRANKS  ·  06-01
Rallybio to Merge with Avenzo, Shifting to Oncology
Rallybio agrees to acquire Avenzo Therapeutics in merger, backed by USD 215 million private placement
Reuters  ·  06-01
Rallybio agrees to acquire Avenzo Therapeutics in merger, backed by USD 215 million private placement
Rallybio - Pre-Deal Rallybio Equityholders to Own 2.8%, Avenzo Equityholders 97.2% of Combined Company
THOMSON REUTERS  ·  06-01
Rallybio - Pre-Deal Rallybio Equityholders to Own 2.8%, Avenzo Equityholders 97.2% of Combined Company
Rallybio - Athena Countouriotis to Lead Combined Company as Chair, President and CEO
THOMSON REUTERS  ·  06-01
Rallybio - Athena Countouriotis to Lead Combined Company as Chair, President and CEO
Rallybio Corporation and Avenzo Therapeutics Announce Merger Agreement to Advance Next-Generation Oncology Therapies and $215 Million Concurrent Private Placement
THOMSON REUTERS  ·  06-01
Rallybio Corporation and Avenzo Therapeutics Announce Merger Agreement to Advance Next-Generation Oncology Therapies and $215 Million Concurrent Private Placement
Rallybio - Combined Company to Operate as Avenzo Therapeutics, Trade as Avzo on Nasdaq
THOMSON REUTERS  ·  06-01
Rallybio - Combined Company to Operate as Avenzo Therapeutics, Trade as Avzo on Nasdaq
NASDAQ TRADE HALT HALT NEWS PENDING AT 07:55 AM
Reuters  ·  06-01
NASDAQ TRADE HALT HALT NEWS PENDING AT 07:55 AM
ADAR1 Capital Management reports Rallybio common share purchase worth $226,800
Reuters  ·  05-21
ADAR1 Capital Management reports Rallybio common share purchase worth $226,800
ADAR1 Capital Management reports Rallybio common share purchase worth $1.1 million
Reuters  ·  05-16
ADAR1 Capital Management reports Rallybio common share purchase worth $1.1 million
ADAR1 Capital reports $711,243 Rallybio common shares purchase
Reuters  ·  05-14
ADAR1 Capital reports $711,243 Rallybio common shares purchase
Rallybio Q1 FY26 net loss narrows to $8.28 million; revenue flat at $212,000
Reuters  ·  05-14
Rallybio Q1 FY26 net loss narrows to $8.28 million; revenue flat at $212,000
Rallybio initial beneficial ownership filing shows ADAR1 Capital Management stake of 623,879 shares
Reuters  ·  05-07
Rallybio initial beneficial ownership filing shows ADAR1 Capital Management stake of 623,879 shares
BUZZ-U.S. STOCKS ON THE MOVE-eBay, Rallybio, Tyson Foods
Reuters  ·  05-04
BUZZ-U.S. STOCKS ON THE MOVE-eBay, Rallybio, Tyson Foods
BRIEF-Rallybio Corp - Candid Terminates Merger Agreement With Rallybio On May 3, 2026 - SEC Filing
Reuters  ·  05-04
BRIEF-Rallybio Corp - Candid Terminates Merger Agreement With Rallybio On May 3, 2026 - SEC Filing
BUZZ-U.S. STOCKS ON THE MOVE-eBay, Rallybio, Norwegian Cruise
Reuters  ·  05-04
BUZZ-U.S. STOCKS ON THE MOVE-eBay, Rallybio, Norwegian Cruise
Rallybio Corp - Entitled to $50 Mln Parent Termination Fee - SEC Filing
THOMSON REUTERS  ·  05-04
Rallybio Corp - Entitled to $50 Mln Parent Termination Fee - SEC Filing
Rallybio says Candid terminates merger agreement, owes $50 million fee
Reuters  ·  05-04
Rallybio says Candid terminates merger agreement, owes $50 million fee
Rallybio Shares Jump 50.5% at $14.14 Premarket After Ucb Offers $2.2 Bln Deal for Candid
THOMSON REUTERS  ·  05-04
Rallybio Shares Jump 50.5% at $14.14 Premarket After Ucb Offers $2.2 Bln Deal for Candid
BUZZ-Rallybio jumps as UCB steps in with $2.2 bln deal for Candid
Reuters  ·  05-04
BUZZ-Rallybio jumps as UCB steps in with $2.2 bln deal for Candid

Introduction

Company Name.
Rallybio Corp.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Rallybio Corporation, a clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that has completed Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT); and RLYB211 for the prevention of FNAIT. The company is also developing RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for the treatment of complement-mediated ophthalmic diseases; RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB331, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. It entered into a strategic alliance with AbCellera to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases. Rallybio has collaboration with Exscientia for the development of small molecule therapeutics for rare diseases; and collaboration agreement with Johnson & Johnson to provide pregnant individuals therapeutic solutions at risk of fetal and neonatal alloimmune thrombocytopenia. The company was founded in 2018 and is headquartered in New Haven, Connecticut.
Issue price:
--